Improving MRI-based dosimetry for holmium-166 transarterial radioembolization using a nonrigid image registration for voxelwise calculation
- PMID: 36202392
- DOI: 10.1002/mp.16014
Improving MRI-based dosimetry for holmium-166 transarterial radioembolization using a nonrigid image registration for voxelwise calculation
Abstract
Background: Transarterial radioembolization (TARE) is a treatment modality for liver tumors during which radioactive microspheres are injected into the hepatic arterial system. These microspheres distribute throughout the liver as a result of the blood flow until they are trapped in the arterioles because of their size. Holmium-166 (166 Ho)-loaded microspheres used for TARE can be visualized and quantified with MRI, as holmium is a paramagnetic metal and locally increases the transverse relaxation rate . The current 166 Ho quantification method does not take regional differences in baseline values (such as between tumors and healthy tissue) into account, which intrinsically results in a systematic error in the estimated absorbed dose distribution. As this estimated absorbed dose distribution can be used to predict response to treatment of tumors and potential toxicity in healthy tissue, a high accuracy of absorbed dose estimation is required.
Purpose: To evaluate pre-existing differences in distributions between tumor tissue and healthy tissue and assess the feasibility and accuracy of voxelwise subtraction-based calculation for MRI-based dosimetry of holmium-166 transarterial radioembolization (166 Ho TARE).
Methods: MRI data obtained in six patients who underwent 166 Ho TARE of the liver as part of a clinical study was retrospectively evaluated. Pretreatment differences in distributions between tumor tissue and healthy tissue were characterized. Same-day pre- and post-treatment maps were aligned using a deformable registration algorithm and subsequently subtracted to generate voxelwise maps and resultant absorbed dose maps. Image registration accuracy was quantified using the dice similarity coefficient (DSC), relative overlay (RO), and surface dice (≤4 mm; SDSC). Voxelwise subtraction-based absorbed dose maps were quantitatively (root-mean-square error, RMSE) and visually compared to the current MRI-based mean subtraction method and routinely used SPECT-based dosimetry.
Results: Pretreatment values were lower in tumors than in healthy liver tissue (mean 36.8 s-1 vs. 55.7 s-1 , P = 0.004). Image registration improved the mean DSC of 0.83 (range: 0.70-0.88) to 0.95 (range: 0.92-0.97), mean RO of 0.71 (range 0.53-0.78) to 0.90 (range: 0.86-0.94), and mean SDSC ≤4 mm of 0.47 (range: 0.28-0.67) to 0.97 (range: 0.96-0.98). Voxelwise subtraction-based absorbed dose maps yielded a higher tumor-absorbed dose (median increase of 9.0%) and lower healthy liver-absorbed dose (median decrease of 13.8%) compared to the mean subtraction method. Voxelwise subtraction-based absorbed dose maps corresponded better to SPECT-based absorbed dose maps, reflected by a lower RMSE in three of six patients.
Conclusions: Voxelwise subtraction presents a robust alternative method for MRI-based dosimetry of 166 Ho microspheres that accounts for pre-existing differences, and appears to correspond better with SPECT-based dosimetry compared to the currently implemented mean subtraction method.
Keywords: SIRT; TARE; deformable; dosimetry; liver; registration.
© 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.
Similar articles
-
Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery.Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4705-4715. doi: 10.1007/s00259-022-05902-w. Epub 2022 Jul 13. Eur J Nucl Med Mol Imaging. 2022. PMID: 35829749 Free PMC article. Clinical Trial.
-
Magnetic resonance imaging-based radiation-absorbed dose estimation of 166Ho microspheres in liver radioembolization.Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e437-44. doi: 10.1016/j.ijrobp.2011.12.085. Int J Radiat Oncol Biol Phys. 2012. PMID: 22633554
-
Retrospective SPECT/CT dosimetry following transarterial radioembolization.J Appl Clin Med Phys. 2021 Apr;22(4):143-150. doi: 10.1002/acm2.13213. Epub 2021 Mar 12. J Appl Clin Med Phys. 2021. PMID: 33710776 Free PMC article.
-
Holmium-166 Radioembolization: Current Status and Future Prospective.Cardiovasc Intervent Radiol. 2022 Nov;45(11):1634-1645. doi: 10.1007/s00270-022-03187-y. Epub 2022 Jun 21. Cardiovasc Intervent Radiol. 2022. PMID: 35729423 Free PMC article. Review.
-
Holmium-166 Microsphere Radioembolization of Hepatic Malignancies.Semin Nucl Med. 2019 May;49(3):237-243. doi: 10.1053/j.semnuclmed.2019.01.008. Epub 2019 Feb 1. Semin Nucl Med. 2019. PMID: 30954190 Review.
Cited by
-
Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial).Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2085-2097. doi: 10.1007/s00259-024-06630-z. Epub 2024 Feb 8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38329507 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17-29.
-
- Hermann AL, Dieudonne A, Ronot M, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020:191606.
-
- Bastiaannet R, van Roekel C, Smits MLJ, et al. First evidence for a dose-response relationship in patients treated with (166)Ho radioembolization: a prospective study. J Nucl Med. 2020;61(4):608-612.
-
- Roosen J, Klaassen NJM, Westlund Gotby LEL, et al. To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging. 2021.
-
- Klaassen NJM, Arntz MJ, Gil Arranja A, Roosen J, Nijsen JFW. The various therapeutic applications of the medical isotope holmium-166: a narrative review. EJNMMI Radiopharm Chem. 2019;4(1):19.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials